Short-Term DOAC Cuts Bleeding After Heart Device Procedure
A 1-year analysis of the ANDES trial found less bleeding with short-term DOAC therapy than with DAPT after left atrial appendage closure.
Updated on Nov. 11, 2026 in Heart Disease

Researchers reported that bleeding at one year was less common in patients given 60 days of direct oral anticoagulants (DOACs) than in those given dual antiplatelet therapy (DAPT) after left atrial appendage closure. Thromboembolic event rates did not differ between the two groups.
Why it matters
Left atrial appendage closure is used to reduce stroke risk in patients with atrial fibrillation, and the choice of post-procedure antithrombotic therapy affects how often patients bleed. The findings suggest a shorter anticoagulant course may lower bleeding risk without increasing thromboembolic events in this population.
The analysis covered 510 patients with a mean age of 77, of whom 77% had a prior bleeding event, split between 257 DAPT and 253 DOAC patients. Imaging was completed in 74.3% of surviving patients, leaving the 1-year device thrombosis comparison incompletely verified.
The players
Boston Scientific
A medical device manufacturer that disclosed financial relationships connected to the study.
Abbott
A global healthcare company that disclosed financial relationships connected to the study.
The details
Patients were assigned to either 60 days of DAPT or a DOAC, and about 78% in both groups switched to single antiplatelet therapy at 60 days. Investigators at each center reported adverse events, and no committee adjudicated them.
Timeline
60 days: Patients in both groups were assessed at the short-term therapy endpoint.
1 year: Clinical and imaging outcomes were assessed.
October 31, 2026: Research letter published online in JACC.
Health Landscape
The ANDES trial is one of several randomized studies testing how long anticoagulation should follow left atrial appendage closure, a procedure used as an alternative to long-term blood thinners in patients with atrial fibrillation. The one-year results add evidence on bleeding trade-offs as clinicians weigh shorter antithrombotic regimens against device-related clotting risk.
Patients weighing left atrial appendage closure may discuss with their cardiologist whether a short DOAC course or DAPT suits their bleeding history. The findings do not yet change standard practice, and treatment decisions remain individualized.
The takeaway
Shorter anticoagulant therapy after left atrial appendage closure may reduce bleeding without raising clot risk in the short term. Longer follow-up and better imaging completion are needed before the late device-thrombosis signal can be settled.
Further reading
Explore more on Heart Disease for background on treatments that prevent stroke and bleeding.
Source note: This article includes information reported by Medscape.



